The challenge for other contenders is getting CBD to penetrate the epidermis. Without Permetrex, BOT wouldn't exist. So it's likely not a lack of desire holding others back, but a lack of capacity to deliver to the dermis. We saw early evidence that we have a decent shot at success from the phase 1 results. If we can replicate in phase 2, our little tubes of gold could be Crossing Counters all over the place..
Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-125
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
-0.008(2.11%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 34.8¢ | $405.9K | 1.152M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 252932 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 128093 | 9 |
View Market Depth
| Last trade - 12.19pm 27/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
